Patents Assigned to Allelix Neuroscience Inc.
-
Patent number: 7019024Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 9, 2001Date of Patent: March 28, 2006Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 6667336Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 15, 2002Date of Patent: December 23, 2003Assignees: NPS Allelix Corp., Allelix Neuroscience, Inc.Inventors: Zhaoqing Wang, William Delaney, Ashok Tehim, Shawn Maddaford, Ian Egle, Richard Schumacher, Allen T. Hopper
-
Patent number: 6251617Abstract: Provided are, among other things, nucleic acid sequences encoding the GlyT1d form of glycine transporter, vectors, methods of producing the transporter, and methods for identifying bioactive agents.Type: GrantFiled: September 14, 1999Date of Patent: June 26, 2001Assignee: Allelix Neuroscience, Inc.Inventors: Vivian R. Albert, Leslie R. Z. Kowalski
-
Patent number: 6191165Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 30, 1997Date of Patent: February 20, 2001Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 6166072Abstract: Described herein are compounds having the general formula: ##STR1## wherein: Ar.sup.1 and Ar.sup.2 are independently selected aryl groups, optionally substituted with substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkanoyl, aralkyl, aralkyloxy, halo, NO.sub.2, Ph, CF.sub.3, CN, OH, methylenedioxy, ethylenedioxy, SO.sub.2 NRR', NRR', CO.sub.2 R (where R and R' are independently selected from the group consisting of H and alkyl) and a second aryl group, which may be substituted as above;wherein any cycloalkyl or aryl substituent is linked to Ar.sup.1 or Ar.sup.2 by a bridging element which may be a single bond, a vinylene group, an ethynylene group, a Z group, a --Z--(CH.sub.2).sub.n -- group, a --(CH.sub.2).sub.n --Z-- group, or a --Z--(CH.sub.2).sub.n --Z-- group, where Z represents an O atom, a S atom, an NH group or an N-alkyl group, and n is an integer from 1 to 4;wherein Ar.sup.1 and Ar.sup.Type: GrantFiled: June 29, 1999Date of Patent: December 26, 2000Assignee: Allelix Neuroscience, Inc.Inventors: Stanley Charles Bell, Michael De Vivo, Allen Hopper, Methvin Isaac, Anne O'Brien, Vassil Ilya Ognyanov, Richard Schumacher
-
Patent number: 6162824Abstract: Described herein are compounds which have the general formula: ##STR1## or a prodrug or pharmaceutically acceptable salt, solvate or hydrate thereof wherein:R.sup.1 is selected from the group consisting of H, alkyl and the counter ion for a basic addition salt;X is selected from the group consisting of CR.sup.9 R.sup.10, S, O, SO, SO.sub.2, NH and N-alkyl;R.sup.2, R.sup.3, R.sup.4, R.sup.9 and R.sup.10 are independently selected from the group consisting of H and alkyl;R.sup.5 and R.sup.6 are independently selected from the group consisting of H, alkyl and phenyl, or, alternatively, R.sup.5 and R.sup.6 together may form a methylene group or a 3- to 6-membered a spirocyclic group;wherein, when X is CR.sup.9 R.sup.10, one or both pairs of R.sup.5 and R.sup.9 or R.sup.6 and R.sup.10 may join to form a double or triple bondR.sup.7 is selected from the group consisting of Formula II-V: ##STR2## which are all optionally substituted, at nodes other than R.sup.Type: GrantFiled: July 30, 1999Date of Patent: December 19, 2000Assignee: Allelix Neuroscience Inc.Inventors: Vassil I. Ognyanov, Allen Hopper, Stanley Charles Bell, Eric A. Meade, Michael De Vivo
-
Patent number: 6103743Abstract: Described herein are compounds having the general formula: ##STR1## Ar.sub.1 and Ar.sub.2 are independently selected aryl groups, optionally substituted with substituents selected from the group consisting of alkyl, cycloalkyl, alkoxy, alkanoyl, aralkyl, aralkyloxy, halo, NO.sub.2, Ph, CF.sub.3, CN, OH, methylenedioxy, ethylenedioxy, SO.sub.2 NRR', NRR', CO.sub.2 R (where R and R' are independently selected from the group consisting of H and alkyl) and a second aryl group, which may be substituted as above;wherein any cycloalkyl or aryl substituent is linked to Ar.sub.1 or Ar.sub.2 by a bridging element which may be a single bond, a vinylene group, an ethynylene group, a Z group, a --Z--(CH.sub.2).sub.n -- group, a --(CH.sub.2).sub.n --Z-- group, or a --Z--(CH.sub.2).sub.n --Z-- group, where Z represents an O atom, a S atom, an NH group or an N-alkyl group, and n is an integer from 1 to 4;wherein Ar.sub.1 and Ar.sub.Type: GrantFiled: August 6, 1999Date of Patent: August 15, 2000Assignee: Allelix Neuroscience, Inc.Inventors: Stanley Charles Bell, Kathleen Da Silva, Allen Hopper, Methvin Isaac, Eric A. Meade, Vassil Ilya Ognyanov, Abdelmalik Slassi
-
Patent number: 6008015Abstract: Provided are, among other things, nucleic acid sequences encoding the GlyT1d form of glycine transporter, vectors, methods of producing the transporter, and methods for identifying bioactive agents.Type: GrantFiled: April 11, 1997Date of Patent: December 28, 1999Assignee: Allelix Neuroscience Inc.Inventors: Vivian R. Albert, Leslie R. Z. Kowalski
-
Patent number: 6001854Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the following formulas I and II: ##STR1## or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 30, 1997Date of Patent: December 14, 1999Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 5968823Abstract: The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.Type: GrantFiled: February 9, 1998Date of Patent: October 19, 1999Assignee: Allelix Neuroscience Inc.Inventors: Laurence A. Borden, Michael De Vivo, Midori Yokoyama, Vivian R. Albert
-
Patent number: 5919653Abstract: The invention provides nucleic acids and proteins derived from the sequence of the human GlyT-2 transporter of the amino acid glycine.Type: GrantFiled: August 20, 1996Date of Patent: July 6, 1999Assignee: Allelix Neuroscience Inc.Inventors: Vivian R. Albert, Leslie R. Z. Kowalski, Laurence A. Borden, Jeffrey F. McKelvy
-
Patent number: 5824486Abstract: The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.Type: GrantFiled: May 31, 1996Date of Patent: October 20, 1998Assignee: Allelix Neuroscience Inc.Inventors: Laurence A. Borden, Michael De Vivo, Midori Yokoyama, Vivian R. Albert